糖尿病与肝细胞癌风险。
Diabetes Mellitus and Risk of Hepatocellular Carcinoma.
机构信息
Department of Hepatology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.
Department of Echocardiography, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.
出版信息
Biomed Res Int. 2017;2017:5202684. doi: 10.1155/2017/5202684. Epub 2017 Dec 12.
Abstract
The occurrence of hepatocellular carcinoma (HCC) is two to three times higher in patients with diabetes mellitus (DM), the prevalence of which is increasing sharply worldwide. The purpose of this review was to describe clinical links between DM and HCC and potential biological mechanisms that may account for this association. We evaluated the role of potential pathways that could account for the development of HCC with different etiologies in the presence of DM. In addition, we also briefly discuss the potential effect of other factors such as type and dosage of antidiabetic medicines and duration of DM on HCC risk.
摘要
肝细胞癌（HCC）在糖尿病（DM）患者中的发生率要高出两到三倍，而全球范围内 DM 的患病率也在急剧上升。本综述旨在描述 DM 与 HCC 之间的临床联系，以及可能解释这种关联的潜在生物学机制。我们评估了在存在 DM 的情况下，不同病因 HCC 发展的潜在途径。此外，我们还简要讨论了其他因素（如降糖药物的类型和剂量以及 DM 的持续时间）对 HCC 风险的潜在影响。
相似文献
1
Diabetes Mellitus and Risk of Hepatocellular Carcinoma.糖尿病与肝细胞癌风险。
Biomed Res Int. 2017;2017:5202684. doi: 10.1155/2017/5202684. Epub 2017 Dec 12.
2
Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?肥胖相关性肝细胞癌：大海捞针？
Adv Exp Med Biol. 2018;1061:63-77. doi: 10.1007/978-981-10-8684-7_6.
3
Introduction.引言。
Adv Exp Med Biol. 2018;1061:1-2. doi: 10.1007/978-981-10-8684-7_1.
4
Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.糖尿病与肝细胞癌：病理生理学联系与药物治疗管理。
Biomed Pharmacother. 2018 Oct;106:991-1002. doi: 10.1016/j.biopha.2018.06.095. Epub 2018 Jul 14.
5
The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.糖尿病对肝细胞癌发生和预后的影响：前瞻性队列研究的荟萃分析。
PLoS One. 2011;6(12):e27326. doi: 10.1371/journal.pone.0027326. Epub 2011 Dec 21.
6
Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma?糖尿病：肝癌的“真正”独立危险因素？
Hepatobiliary Pancreat Dis Int. 2009 Oct;8(5):465-73.
7
Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.糖尿病患者肝细胞癌的风险与抗糖尿病治疗相关的风险降低：一项基于人群的队列研究。
Am J Gastroenterol. 2012 Jan;107(1):46-52. doi: 10.1038/ajg.2011.384. Epub 2011 Nov 15.
8
Diabetes is not an independent risk factor for hepatocellular carcinoma.糖尿病不是肝细胞癌的独立危险因素。
Diabetes Metab Res Rev. 2013 Oct;29(7):515-24. doi: 10.1002/dmrr.2422.
9
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌：一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
10
Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies.2型糖尿病对慢性肝病患者肝细胞癌风险的影响：队列研究的荟萃分析
Eur J Cancer Prev. 2015 Mar;24(2):89-99. doi: 10.1097/CEJ.0000000000000038.
引用本文的文献
1
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.45岁及以上成年人中与非酒精性脂肪性肝炎相关的肝癌的全球、区域和国家负担：来自全球疾病负担研究（GBD）2021的分析及到2050年的预测
Front Nutr. 2025 Aug 19;12:1651357. doi: 10.3389/fnut.2025.1651357. eCollection 2025.
2
Bridging diabetes and cancer: harnessing biomarkers as dual sentinels for diagnosis, prognosis, and therapeutic advancements.连接糖尿病与癌症：利用生物标志物作为诊断、预后及治疗进展的双重哨兵
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 19. doi: 10.1007/s00210-025-04209-5.
3
Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis.非酒精性脂肪性肝病和2型糖尿病患者使用他汀类药物与肝细胞癌风险：一项综述和荟萃分析
BMC Cancer. 2025 May 14;25(1):875. doi: 10.1186/s12885-025-14299-2.
4
Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study).不可切除肝细胞癌患者对阿替利珠单抗联合贝伐单抗无反应的预测因素：一项多中心真实世界研究（HCC-AB研究）
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102513. doi: 10.1016/j.jceh.2025.102513. Epub 2025 Feb 8.
5
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.创新药物在2型糖尿病和肥胖症中的首次应用及其对代谢功能障碍相关脂肪性肝炎（MASH）相关纤维化和肝硬化的影响。
J Clin Med. 2025 Feb 7;14(4):1042. doi: 10.3390/jcm14041042.
6
Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus.2型糖尿病墨西哥裔美国人肝细胞癌的风险与预后
J Hepatocell Carcinoma. 2025 Jan 21;12:93-106. doi: 10.2147/JHC.S477141. eCollection 2025.
7
Metformin in Antiviral Therapy: Evidence and Perspectives.二甲双胍在抗病毒治疗中的应用：证据与展望
Viruses. 2024 Dec 18;16(12):1938. doi: 10.3390/v16121938.
8
Altered Metabolites in Hepatocellular Carcinoma (HCC) Paving the Road for Metabolomics Signature and Biomarkers for Early Diagnosis of HCC.肝细胞癌（HCC）中代谢物的改变为HCC早期诊断的代谢组学特征和生物标志物铺平了道路。
Cureus. 2024 Oct 20;16(10):e71968. doi: 10.7759/cureus.71968. eCollection 2024 Oct.
9
Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study.日本代谢相关脂肪性肝病（MASLD）伴糖尿病患者，根据肥胖程度和向肝硬化进展进行风险分层的肝细胞癌筛查：成本效益研究。
BMJ Open. 2024 Nov 5;14(11):e080549. doi: 10.1136/bmjopen-2023-080549.
10
Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.非酒精性脂肪性肝病和代谢相关脂肪性肝病之间的重叠组对肝脏研究更有利。
JGH Open. 2024 Oct 13;8(10). doi: 10.1002/jgh3.70039. eCollection 2024 Oct.
本文引用的文献
1
Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.糖尿病、代谢合并症与肝细胞癌风险：两项前瞻性队列研究结果。
Hepatology. 2018 May;67(5):1797-1806. doi: 10.1002/hep.29660. Epub 2018 Mar 26.
2
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?胰岛素抵抗与代谢灵活性降低：非酒精性脂肪性肝病的原因还是后果？
Clin Sci (Lond). 2017 Nov 6;131(22):2701-2704. doi: 10.1042/CS20170987. Print 2017 Nov 15.
3
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.2型糖尿病与肝细胞癌风险：聚焦非酒精性脂肪性肝病
Ann Transl Med. 2017 Jul;5(13):270. doi: 10.21037/atm.2017.04.41.
4
Association Between Hepatocellular Carcinoma and Type 2 Diabetes Mellitus in Chinese Hepatitis B Virus Cirrhosis Patients: A Case-Control Study.中国乙型肝炎病毒肝硬化患者肝细胞癌与2型糖尿病之间的关联：一项病例对照研究
Med Sci Monit. 2017 Jul 9;23:3324-3334. doi: 10.12659/msm.902440.
5
[The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].[非酒精性脂肪性肝病中肝细胞癌的发生发展]
Korean J Gastroenterol. 2017 Jun 25;69(6):348-352. doi: 10.4166/kjg.2017.69.6.348.
6
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.非酒精性脂肪性肝炎中的肝细胞癌：当前认知及管理意义
World J Hepatol. 2017 Apr 18;9(11):533-543. doi: 10.4254/wjh.v9.i11.533.
7
Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China.在中国，未经治疗的慢性丙型肝炎患者中，糖尿病会增加肝细胞癌的发病风险。
Medicine (Baltimore). 2017 Mar;96(13):e6508. doi: 10.1097/MD.0000000000006508.
8
Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study.糖尿病、肝细胞癌与丙型肝炎感染患者的死亡率：一项基于人群的队列研究。
J Gastroenterol Hepatol. 2017 Jul;32(7):1355-1362. doi: 10.1111/jgh.13670.
9
Diabetes mellitus and metformin in hepatocellular carcinoma.糖尿病与二甲双胍在肝细胞癌中的作用
World J Gastroenterol. 2016 Jul 21;22(27):6100-13. doi: 10.3748/wjg.v22.i27.6100.
10
Hepatitis C Virus, Insulin Resistance, and Steatosis.丙型肝炎病毒、胰岛素抵抗与脂肪变性。
J Clin Transl Hepatol. 2016 Mar 28;4(1):66-75. doi: 10.14218/JCTH.2015.00051. Epub 2016 Mar 15.
Zotero 插件